China Prazosin Market Size, Share, Trends & Forecast 2020-2026


Posted August 13, 2020 by preetipandey

China prazosin market is estimated to decline during the forecast period. China is among the emerging nations facing a burden of the continuouse

 
China prazosin market is estimated to decline during the forecast period. China is among the emerging nations facing a burden of the continuous increase in high blood pressure. Lack of physical activity, obese population, alcohol consumption, and smoking are some of the major factors that lead to the increasing incidences of high blood pressure. The rising aging population may further increase the risk of hypertension in China. As per the United Nations (UN), in 2019, the percentage of the population aged 65 years and over in the country was 11.5%, which is expected to reach 16.9% by 2030. With the age, arteries get stiffer and thereby blood pressure goes up. Hypertension is one of the primary modifiable risk factors for CVD and its prevalence as well as severity both increase with age. However, the discontinuation of prazosin drugs due to various side effects further projected to decline the market growth during the forecast period.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/china-prazosin-market

China prazosin market is segmented on the basis of application into cardiovascular disease, neurological syndromes, prostate disorders, and kidney disorders. The CVD segment accounted for the significant share in the China prazosin market. CVDs claim to take more lives each year than all forms of cancer and chronic lower respiratory diseases altogether. Thus, Prazosin is one of the treatments used for CVD mainly high BP and strokes. For instance, Minipress is specified for the treatment of hypertension, to control BP. Lowering blood pressure decreases the risk of fatal and nonfatal cardiovascular events, mainly strokes and myocardial infarction.

Browse for Full Report Description@https://www.omrglobal.com/industry-reports/china-prazosin-market

The companies which are contributing to the growth of the China prazosin market include Ajinomoto Co., Inc., Standard Chem and Pharmaceuticals Co. Ltd., Sun Pharmaceuticals Industries Ltd., Merck KGaA, Mylan N.V., Pfizer Inc., and others. The market players are considerably contributing to the market by the adoption of various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.

Market Segmentation

China Prazosin Market by Application
Cardiovascular Disease(CVD)
Neurological Syndromes
Prostate Disorders
Kidney Disorders
Company Profiles

Ajinomoto Co., Inc.
Johnlee Pharmaceuticals Pvt. Ltd.
Merck KGaA
Pfizer Inc.
R&D Systems Inc.
Renata Ltd.
Mylan N.V.
Standard Chem and Pharmaceuticals Co. Ltd.
Sun Pharmaceuticals Industries Ltd.
Teva Pharmaceuticals Industries Ltd.


For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/china-prazosin-market



About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By preeti
Phone +91 780-304-0404
Country India
Categories Business
Tags china prazosin market
Last Updated August 13, 2020